| Original language | English (US) |
|---|---|
| Pages (from-to) | 106-108 |
| Number of pages | 3 |
| Journal | Circulation |
| Volume | 137 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2018 |
Keywords
- Heart failure
- Primary prevention
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Circulation, Vol. 137, No. 2, 2018, p. 106-108.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Prevention of "Failure"
T2 - Is it a failure of prevention?
AU - Nambi, Vijay
AU - Deswal, Anita
AU - Ballantyne, Christie M.
N1 - Funding Information: Dr Nambi reports the following: research grant, (site Principal Investigator) Merck; Regional Advisory Board (once), Sanofi Regeneron; co-investigator provisional patent (# 61721475) entitled, "Biomarkers to Improve Prediction of Heart Failure Risk," filed by Baylor College of Medicine, Roche; an honorarium, Siemens for event adjudication. Dr Nambi is supported by an Investigator-Initiated Research grant from the Department of Veterans Affairs Clinical Science Research & Development grant (1I01CX001112-01: Nambi V [PI] 04/01/2014-03/31/2019 Biomarker Guided Therapies in Stage A/B Heart Failure). Dr Deswal reports no conflicts. Dr Ballantyne reports the following: grant/research support-all significant (all paid to institution, not individual): Abbott Diagnostic, Amarin, Amgen, Ackea, Eli Lilly, Esperion, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, Takeda, NIH, AHA, ADA; Consultant- Abbott Diagnostics, Amarin, Amgen∗, Astra Zeneca∗, Ackea, Eli Lilly, Esperion, Matinas BioPharma Inc, Merck∗, Novartis, Pfizer∗, Regeneron, Roche, Sanofi-Synthelabo (∗Significant where noted [>$10 000]; remainder modest [<$10 000]); co-investigator provisional patent (# 61721475) entitled, "Biomarkers to Improve Prediction of Heart Failure Risk," filed by Baylor College of Medicine, Roche. Funding Information: Dr Nambi reports the following: research grant, (site Principal Investigator) Merck; Regional Advisory Board (once), Sanofi Regeneron; co-investigator provisional patent (# 61721475) entitled, “Biomarkers to Improve Prediction of Heart Failure Risk,” filed by Baylor College of Medicine, Roche; an honorarium, Siemens for event adjudication. Dr Nambi is supported by an Investigator-Initiated Research grant from the Department of Veterans Affairs Clinical Science Research & Development grant (1I01CX001112-01: Nambi V [PI] 04/01/2014-03/31/2019 Biomarker Guided Therapies in Stage A/B Heart Failure). Dr Deswal reports no conflicts. Dr Ballantyne reports the following: grant/research support–all significant (all paid to institution, not individual): Abbott Diagnostic, Amarin, Amgen, Ackea, Eli Lilly, Esperion, Novartis, Pfizer, Regener-on, Roche Diagnostic, Sanofi-Synthelabo, Takeda, NIH, AHA, ADA; Consultant– Abbott Diagnostics, Amarin, Amgen*, Astra Zeneca*, Ackea, Eli Lilly, Esperion, Matinas BioPharma Inc, Merck*, Novartis, Pfizer*, Regeneron, Roche, Sanofi-Synthe-labo (*significant where noted [>$10 000]; remainder modest [<$10 000]); co-investigator provisional patent (# 61721475) entitled, “Biomarkers to Improve Prediction of Heart Failure Risk,” filed by Baylor College of Medicine, Roche.
PY - 2018
Y1 - 2018
KW - Heart failure
KW - Primary prevention
UR - http://www.scopus.com/inward/record.url?scp=85043691990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043691990&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.117.030645
DO - 10.1161/CIRCULATIONAHA.117.030645
M3 - Article
C2 - 29311345
AN - SCOPUS:85043691990
SN - 0009-7322
VL - 137
SP - 106
EP - 108
JO - Circulation
JF - Circulation
IS - 2
ER -